AI Drug Discovery: Clinical Outcomes Still Limited

Nature Reviews Drug Discovery critically reviewed the progress and limitations of AI drug discovery. While various AI methodologies have been developed and benchmarked, it assessed that clinically meaningful outcomes in rapidly delivering safer and more effective medicines to patients remain limited.

The following were cited as major causes:

• Lack of consideration for clinical translatability during the model development stage
• Difficulties in applying AI algorithms to conditional and complex life science data
• Insufficient problem definition and model design relative to actual use cases
• A tendency toward ‘technology push’, where technology development outpaces field needs
• The long time required to operate technologies as sufficiently scalable and accessible systems

It proposed that future benchmarking should go beyond simple model validation to evaluate whether AI tools improve drug discovery decision-making itself. The analysis stated that AI’s contribution to drug discovery can only be proven if research goals and evaluation metrics are aligned with clinical and operational outcomes.